Lishengpharma(SZ:002393) Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2025-09-11 01:13Core Viewpoint - The company has approved the use of idle raised funds for cash management, allowing up to RMB 600 million for purchasing short-term financial products with high safety and liquidity, ensuring it does not affect the implementation of investment projects [1] Group 1: Cash Management Details - The company has invested a total of RMB 70 million in structured deposits at Industrial Bank Co., Ltd. Tianjin Branch [1] - There is no related party relationship between the company and Industrial Bank [1] Group 2: Risk Control Measures - The company aims to control risks by purchasing short-term financial products that are safe and liquid, issued by major commercial banks or securities institutions [3] - The finance department is responsible for managing the purchased financial products and will take timely measures if any risk factors affecting fund safety are identified [3] - The audit department will regularly audit the use and custody of the purchased financial products and report to the board and supervisory committee [3] Group 3: Impact on the Company - The company emphasizes compliance and effective control of investment risks while using idle raised funds for cash management, which will not affect daily operations or the normal progress of investment projects [4] - This cash management approach is expected to improve the efficiency of fund usage and generate investment returns for the company and its shareholders [4] Group 4: Previous Cash Management Activities - As of the announcement date, the total amount of idle raised funds used for cash management that are not yet due is RMB 155 million, which is within the approved limits [4]